News and Announcements
Actinogen Medical Investor Research Update
- Published October 13, 2016 11:22AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
September 27, 2016
Actinogen Medical (ASX:ACW) met again with Baker Young Stockbrokers to discuss Xanamem™’s past resear
Best Risk vs Reward Play in Alzheimer’s Dementia
Baker Young maintains coverage of Actinogen Medical with a BUY recommendation and value ACW $0.39 per share base case and $1.12 per share optimistic case using the probability weighted DCF methodology.
Alastair Murray
Analyst, Baker Young Corporate
“We see XanADu, the Phase II trial of Xanamem™ for the treatment of mild Alzheimer’s disease positioning Actinogen amongst significantly larger peers (see Table inside report). Going forward Actinogen has a strong cash position to progress through the pivotal Phase II clinical trial, which the company hopes will show Xanamem™ to be an effective and safe treatment for mild Alzheimer’s disease. We believe positive results from this Phase II trial will likely result in a significant partnering transaction (potential for a total deal size of up to $1B upfront & milestones + royalties) given the current unmet market need, comparable similar transactions and Big Pharma’s desire to bring new effective treatments for dementia to market. We believe ACW at current levels represents compelling value on a risk-reward basis”
To view the Baker Young Report, please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
